Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Zyversa Therapeutics Inc
ZVSA
Healthcare
Biotechnology
ZyVersa Therapeutics, Inc. is a clinical-stage specialty biopharmaceutical company. The Company is focused on leveraging advanced technologies to develop drugs for patients with chronic renal or inflammatory diseases. Its lead renal drug candidate Cholesterol Efflux Mediator VAR 200 (2-hydroxypropyl-beta-cyclodextrin or 2HBCD) is in development to treat multiple renal indications. Its lead anti...
-inflammatory drug candidate, Inflammasome ASC Inhibitor IC 100, is a humanized monoclonal antibody in development to treat multiple inflammatory diseases. Its renal pipeline is initially focused on rare, chronic glomerular diseases. Its lead indication for VAR 200 is focal segmental glomerulosclerosis (FSGS). VAR 200’s active ingredient, 2HBCD, is comprised of seven sugar molecules bound together in a 3-D ring with a hydrophobic core and hydrophilic exterior. VAR 200 mediates cholesterol efflux both passively and actively by interacting with hydrophilic components of the glomerular membrane.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:ZVSA)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
Next
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Feb 22, 2024 7:47am
New Press Release - ZyVersa Therapeutics Publishes New White Paper Detailing the Role of Inflammasomes and ASC Specks in Neurological Diseases, and Data Supporting Inflammasome ASC Inhibitor IC 100 as a Potential Therapeutic Option
Neurological diseases, which affect up to 16 million people over 18 years old in the US, are the leading cause of physical and cognitive disability.A growing body of evidence supports that activation of more than one type of inflammasome contributes to development of common neurological diseases,...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Feb 14, 2024 7:53am
New Press Release - ZyVersa Therapeutics Highlights Review Article Substantiating That Inflammasome Activation Is Pathogenic in Multiple Neurological Diseases
Up to 16 million adults in the US are living with a neurological disease, the leading cause of physical and cognitive disability, and 1.2 million new cases are diagnosed annually. The review article summarizes data demonstrating that inflammation resulting from activation of more than one type of...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Feb 07, 2024 8:02am
New Press Release - ZyVersa Therapeutics' CEO, Stephen C. Glover to Present at the 2024 BIO CEO & Investor Conference to Provide Corporate Update and Discuss Key Milestones
ZyVersa is advancing a dynamic pipeline of drug candidates with multiple programs built around two proprietary technologies – Cholesterol Efflux Mediator™ VAR 200 for treatment of kidney diseases, and Inflammasome ASC Inhibitor IC 100 for treatment of multiple CNS and peripheral inflammatory...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Jan 31, 2024 7:57am
New Press Release - ZyVersa Therapeutics Highlights Publication Indicating That Inflammasome NLRP3-Mediated Inflammation in Obese Children Leads to Insulin Resistance and Risk of Complications Such as Type 2 Diabetes
Insulin resistance (IR), a common feature of childhood obesity which affects 15 million children and adolescents, is the main driver of obesity-related metabolic complications such as Type 2 diabetes, hypertension, and premature heart disease.This study demonstrated that NLRP3 inflammasome...
read article.
(57)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Jan 25, 2024 9:21am
ZVSA....Meh...it's a pig like all the others
Yesterday was just a "dead cat" bounce
(57)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Jan 24, 2024 11:17am
ZVSA...NR this a.m
On watch list...... recent previous runner on big Volume 64 cents
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Jan 24, 2024 7:57am
New Press Release - ZyVersa Therapeutics Announces Peer-Reviewed Article Supporting the Therapeutic Potential of Targeting ASC Specks During Progression of Alzheimer's Disease
Research demonstrated that activation of the inflammasome/ASC speck pathway has a vital role in synaptic degeneration in Alzheimer’s Disease (AD).ZyVersa is developing IC 100, a monoclonal antibody targeting inflammasome ASC specks to block initiation and perpetuation of damaging inflammation in...
read article.
(57)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Jan 18, 2024 9:17am
ZVSA.....just like "clockwork"..hickory Dickory
Sub 60 pesos.....You've all been had ...again!
(57)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Jan 17, 2024 3:26pm
ZVSA...This is what I'm thinking..and no..I have O position
This will probably get a last minute heroics on volume spike That will be the end of it This is a typical day watching the chasers get fried
(57)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Jan 17, 2024 3:22pm
Buh Bye
loser
(57)
•••
Iseneschal
X
View Profile
View Bullboard History
Comment by
Iseneschal
on Jan 17, 2024 3:16pm
RE:ZVSA....whooop der id is
Seriously ....does anyone believe Mr. M's bs
(57)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Jan 17, 2024 3:14pm
ZVSA....whooop der id is
The Big Bid by Mr. M....LoL
(57)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Jan 17, 2024 1:17pm
ZVSA....40K / 5 mins candle ain't going to cut it
Wasting time
(57)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Jan 17, 2024 1:15pm
ZVSA....amazing how they manip the quote on zero vol
Blowing smoke
(57)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Jan 17, 2024 12:57pm
ZVSA....play x play ...Now red LoL
Now I see the MM is posting big bids....Lol...now that is the signal..."Kiss o Death" Buh Bye !!!
Prev
1
2
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Silvercorp to Acquire Adventus for Implied Consideration of C$0.50 per Share
Meet one of the Strongest Contenders to Lead Canada’s Cannabis Market
Multiple High-Grade Gold Hits at the Tonopah Gold Project Including 90 Meters at 2.0 gpt Gold
An Opportunity to Join Pulsar Helium on the Ground in Minnesota for a Historic Reservoir Flow Test
NOI Filed for Drill Program at Lithium/Uranium Project in Nevada